AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2441648
Drug: Loperamide 0.4
RxNorm normalized name: loperamide 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 0.4 mg/kg/day
Trial: 2441648
Drug: Loperamide 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 0.8 mg/kg/day
Trial: 30350717
Drug: Ocriplasmin injection
RxNorm normalized name: ocriplasmin Injection
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocriplasmin injection (Jetrea®)
Trial: 26181705
Drug: 12-week pharmacotherapy-based
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week pharmacotherapy-based algorithm treatment
Trial: 17213002
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered at 3, 7, and 11 pm (total daily dose, 1200 mg)
Trial: 14586357
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (2 sprays of 400 mcg)
Trial: 14586357
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 sprays)
Trial: 10758957
Drug: Transmyocardial revascularization
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmyocardial revascularization with CO2 laser (TMR) in addition to optimal medical treatment (MT)
Trial: 10758957
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical treatment (MT)
Trial: 8320424
Drug: Ipriflavone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (600 mg/day) + calcium (500 mg/day)
Trial: 16167916
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg/day)
Trial: 3549990
Drug: Adriamycin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (70 mg/m2, slow push, every 3 weeks for seven courses, maximum 550 mg/m2)
Trial: 28497534
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT) - 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 12 months
Trial: 20403351
Drug: Indirab (Vero
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirab (Vero cell based rabies vaccine)
Trial: 20403351
Drug: Verorab (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verorab (reference vaccine)
Trial: 18689364
Drug: Diet S
RxNorm normalized name: Chewable Diet Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet S (24 g soy protein and 70-80 mg isoflavones)
Trial: 18689364
Drug: Diet SD
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet SD (12 g soy protein, 12 g dairy protein, and 70-80 mg isoflavones)
Trial: 18689364
Drug: Diet D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet D (24 g dairy protein without isoflavones)
Trial: 15844839
Drug: Xiong‐gui‐tiao‐xue‐yin (Kyuki‐chouketsu‐in)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiong‐gui‐tiao‐xue‐yin (Kyuki‐chouketsu‐in) at a dose of 6.0 g/day
Trial: 18420851
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg (group D)
Trial: 11394426
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg (group M)
Trial: 9891192
Drug: Buccal prochlorperazine
RxNorm normalized name: prochlorperazine Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal prochlorperazine
Trial: 9891192
Drug: Oral prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prochlorperazine
Trial: 2598991
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of Carbamazepine (CBZ)
Trial: 2598991
Drug: Controlled-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulation of Carbamazepine (CBZ)
Trial: 371974
Drug: 2,3-dihydroxybenzoic acid
RxNorm normalized name: 2,3-dihydroxybenzoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,3-dihydroxybenzoic acid (2,3-DHB) at a dose of 25 mg/kg four times per day
Trial: 28704936
Drug: Nutraceutical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical formulation (berberine 200 mg, monacolin K 3 mg, chitosan 10 mg, coenzyme Q 10 mg)
Trial: 19301720
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg once a day for five days
Trial: 9921943
Drug: Sealed group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealed group (povidone-iodine gel applied to subcutaneous tissue)
Trial: 9921943
Drug: Open group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open group (usual treatment)
Trial: 3281487
Drug: Proguanil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil (200 mg daily)
Trial: 6152120
Drug: Chloroquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (300 mg weekly)
Trial: 30443664
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of corticosteroid injections and strength training/stretching (n=29)
Trial: 30443664
Drug: Corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injections (n=31)
Trial: 26700861
Drug: PEG‐IFN alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alfa‐2a therapy for 48 weeks
Trial: 24340290
Drug: BBTI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBTI treatment
Trial: 17022791
Drug: Amisulpride 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 150 mg/day
Trial: 9926802
Drug: Implantable insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implantable insulin pump
Trial: 9926802
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily insulin injections
Trial: 8067597
Drug: Azelastine, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine, 2 mg bid
Trial: 8067597
Drug: Clemastine fumarate,
RxNorm normalized name: Clemastine Fumarate, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine fumarate, 1.34 mg bid
Trial: 28934950
Drug: Sham-acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-acupuncture treatment
Trial: 25797560
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus daily navitoclax for 12 weeks (arm B)
Trial: 25797560
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus daily navitoclax until disease progression or unacceptable toxicity (arm C)
Trial: 19695189
Drug: High-dose ganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ganciclovir (7.5 mg/kg in inducement phase, 10 mg/kg in maintaining phase)
Trial: 19695189
Drug: Low-dose ganciclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ganciclovir (5 mg/kg in inducement and maintaining phases)
Trial: 17091363
Drug: Depressive symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depressive symptoms measured within 4 weeks after treatment
Trial: 17091363
Drug: Treatment type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type (radical prostatectomy, external beam radiation, or brachytherapy)
Trial: 14727275
Drug: 0.75 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mL/kg of bupivacaine 0.25% with ketamine 0.25 mg/kg
Trial: 14727275
Drug: 0.75 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mL/kg of bupivacaine 0.25% with ketamine 0.5 mg/kg
Trial: 14727275
Drug: 0.75 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mL/kg of bupivacaine 0.25% with ketamine 1 mg/kg
Trial: 14727275
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (bupivacaine 0.25% with ketamine 0.25 mg/kg)
Trial: 11349178
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (0.625 mg) and medroxyprogesterone acetate (5 mg)
Trial: 11349178
Drug: 17beta-estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol (2 mg) and norethindrone acetate (1 mg)
Trial: 9139489
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection of acellular pertussis-diphtheria-tetanus vaccine with Haemophilus influenzae b conjugate vaccine
Trial: 8375540
Drug: Polyacrylamide gel
RxNorm normalized name: polyacrylamide (10000 MW)
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyacrylamide gel (1.5%, 1.6%, 1.7%, 1.8%)
Trial: 8375540
Drug: Polyacrylamide gel
RxNorm normalized name: polyacrylamide (10000 MW)
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyacrylamide gel (1.8%)
Trial: 26684594
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (anti-impulse therapy)
Trial: 23294276
Drug: Tofacitinib 2
RxNorm normalized name: tofacitinib 22 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 2 mg twice daily
Trial: 18590518
Drug: Computerised cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised cognitive behavioural therapy (CBT)
Trial: 18590518
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual by a GP
Trial: 18590518
Drug: Computerised cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised cognitive behavioural therapy in combination with usual GP care
Trial: 16092109
Drug: Long-term antiparkinson
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antiparkinson therapy
Trial: 16092109
Drug: Patients before
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients before therapy
Trial: 12042268
Drug: Double lumen
RxNorm normalized name: SOLUPICC 7-Day Double Lumen PICC Line Supply Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double lumen catheter (CC)
Trial: 10598602
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation for 0 min (sham treatment)
Trial: 6087753
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulfamethoxazole and trimethoprim and ketoconazole
Trial: 30449275
Drug: Fluralaner plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner plus moxidectin (Bravecto® Plus) - minimum dose rates 40 mg/kg and 2 mg/kg, respectively
Trial: 30449275
Drug: Emodepside plus
RxNorm normalized name: Emodepside
DrugBank: Emodepside (DB11403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside plus praziquantel (Profender®) - minimum dose rates 3 mg/kg and 12 mg/kg, respectively
Trial: 27320173
Drug: Simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin plus extended release niacin (ERN), 1500 to 2000 mg/day
Trial: 22898678
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg per day
Trial: 20693876
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intravenous ketamine on induction of anesthesia and continuous infusion at 10 microg kg(‐1) min(‐1) until wound closure
Trial: 20693876
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intravenous ketamine
Trial: 10561942
Drug: 0.05 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 per cent isotretinoin gel (Isotrex)
Trial: 2070703
Drug: Amantadine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100 mg nocte)
Trial: 1673628
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg twice daily)
Trial: 3053312
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg nocte)
Trial: 6680214
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium fluoride gel
Trial: 25548261
Drug: High-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat diet (CETP rs3764261 CC genotype)
Trial: 25548261
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet (CETP rs3764261 CC genotype)
Trial: 25548261
Drug: Low-carbohydrate/high-fat weight-loss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate/high-fat weight-loss diet (CETP rs3764261 CC genotype)
Trial: 11694609
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/d)
Trial: 22414819
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/d) after vitamin A supplementation (200,000 IU)
Trial: 17595779
Drug: 7 or
RxNorm normalized name: Cyanocobalamin Co 57 Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 or more courses of intravenous topotecan
Trial: 17595779
Drug: 6 or
RxNorm normalized name: Serc-16 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 or fewer courses of intravenous topotecan
Trial: 17595779
Drug: topotecan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topotecan treatment
Trial: 11991908
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (non-contact laser therapy)
Trial: 7630998
Drug: Dance for
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance for Health intervention (aerobic dance program, health education curriculum twice a week, dance-oriented physical education class three times a week)
Trial: 22452620
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition (35 kcal/Kg/day for 4 weeks followed by oral nutritional support for 2 months)
Trial: 19167189
Drug: Combined transbuccal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined transbuccal and intra-oral approach
Trial: 19167189
Drug: Intra-oral alone
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-oral alone
Trial: 15364688
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of botulinum toxin type A
Trial: 12324288
Drug: Dietary counseling
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary counseling with an extra 350 micro g folate derived from food/d
Trial: 7857345
Drug: Pidotimod 800
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod 800 mg sachets after fasting
Trial: 7857345
Drug: Pidotimod 800
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod 800 mg sachets after a standard meal
Trial: 7857345
Drug: Pidotimod 800
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod 800 mg ampoules after fasting
Trial: 7857345
Drug: Pidotimod 800
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod 800 mg ampoules after a standard meal
Trial: 7857345
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both formulations (sachets and ampoules)
Trial: 2632449
Drug: Systemic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic aspirin
Trial: 662249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of urea and prostaglandin
Trial: 26571987
Drug: Ethanolic leaf
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanolic leaf extracts of Ocimum sanctum (EtOS) 300 mg per day for 30 days
Trial: 22145768
Drug: Internet-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based treatment group
Trial: 7505423
Drug: Aspartame (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (34 mg/kg single morning dose)
Trial: 27056638
Drug: Ipragliflozin 25-50
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 25-50 mg/day
Trial: 27056638
Drug: Alogliptin 12.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5-25 mg/day
Trial: 20479759
Drug: Weekly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly high-dose EPO for 3 months
Trial: 18349391
Drug: Chemo-endocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-endocrine therapy (CMF chemotherapy for 6 cycles followed by goserelin)
Trial: 18349391
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (goserelin or tamoxifen)
Trial: 18349391
Drug: Chemo-endocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-endocrine therapy (CMF followed by tamoxifen for 5 years)
Trial: 14646613
Drug: etilevodopa/carbidopa swallowed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etilevodopa/carbidopa swallowed tablets
Trial: 14646613
Drug: etilevodopa/carbidopa tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etilevodopa/carbidopa tablets dissolved in water
Trial: 14646613
Drug: etilevodopa oral
RxNorm normalized name: etilevodopa
DrugBank: Etilevodopa (DB06535)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etilevodopa oral solution with carbidopa tablets
Trial: 14646613
Drug: standard levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard levodopa/carbidopa tablets
Trial: 10961868
Drug: Weekly PEG‐Asp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly PEG‐Asp dosing
Trial: 1312773
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of folic acid daily for 6 months
Trial: 22075942
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 6 months
Trial: 1289091
Drug: Supplementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation of normal diet with 3 g of omega-3 polyunsaturated fatty acids per day for 6 months (treatment group)
Trial: 1289091
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy only (control group)
Trial: 2865857
Drug: Celiprolol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (300 mg per day)
Trial: 2865857
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 mg per day)
Trial: 27100799
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy (CBGT) for 12 weeks
Trial: 22844979
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ketamine lozenge
Trial: 15949774
Drug: Conservative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatments for low back pain
Trial: 11908905
Drug: CLA supplementation
RxNorm normalized name: CLA
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLA supplementation (1.5 g daily)
Trial: 10096389
Drug: DHEA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA treatment (50 mg orally once a day for 6 months)
Trial: 10096389
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (one time a day for 6 months)
Trial: 30782991
Drug: Sequential CQ-PQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential CQ-PQ treatment (arm 1)